• Boston Scientific posted Q2 net sales of $5.44 billion, up 7.5% year over year.
• Net income attributable to common shareholders rose 13.8% to $907 million; diluted EPS increased 15.2% to $0.61.
• Gross profit margin widened 3 percentage points to 70.7%, helped by higher-margin product mix, tariff recovery benefits, lower inventory charges, offset by FX.
• MedSurg net sales climbed 5.9% to $1.82 billion, led by Endoscopy; Cardiovascular rose 8.3% to $3.62 billion, driven by coronary therapies and Electrophysiology.
• Boston Scientific outlined a pending acquisition of Penumbra valued at about $14.5 billion, expected to close in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000885725-26-000053), on August 03, 2026, and is solely responsible for the information contained therein.